UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/764,215	01/23/2004	Boon Peng Chew	P142M	9145
	7590 05/03/201 R & GAMBLE COMP	EXAMINER		
Global Legal Do		VAKILI, ZOHREH		
Sycamore Building - 4th Floor 299 East Sixth Street CINCINNATI, OH 45202			ART UNIT	PAPER NUMBER
			1629	
			MAIL DATE	DELIVERY MODE
			05/03/2011	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/764,215	CHEW ET AL.	
Examiner	Art Unit	
ZOHREH VAKILI	1629	

The MAILING DATE of this communication appears of	n the cover sheet with the correspondence address
THE REPLY FILED <u>04 March 2011</u> FAILS TO PLACE THIS APPLICA	ATION IN CONDITION FOR ALLOWANCE.
application in condition for allowance; (2) a Notice of Appeal (wi for Continued Examination (RCE) in compliance with 37 CFR 1.	s: (1) an amendment, affidavit, or other evidence, which places the th appeal fee) in compliance with 37 CFR 41.31; or (3) a Request
no event, however, will the statutory period for reply expire later that	Action, or (2) the date set forth in the final rejection, whichever is later. In
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which have been filed is the date for purposes of determining the period of extension under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shorten set forth in (b) above, if checked. Any reply received by the Office later than the may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	and the corresponding amount of the fee. The appropriate extension fee ed statutory period for reply originally set in the final Office action; or (2) as
 The Notice of Appeal was filed on <u>04 January 2011</u>. A brief in c the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any appeal. Since a Notice of Appeal has been filed, any reply must <u>AMENDMENTS</u> 	extension thereof (37 CFR 41.37(e)), to avoid dismissal of the
3. The proposed amendment(s) filed after a final rejection, but price (a) They raise new issues that would require further considers (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better for appeal; and/or	ation and/or search (see NOTE below);
(d) ☐ They present additional claims without canceling a corres NOTE: (See 37 CFR 1.116 and 41.33(a)).	
4. The amendments are not in compliance with 37 CFR 1.121. Se	e attached Notice of Non-Compliant Amendment (PTOL-324).
5. Applicant's reply has overcome the following rejection(s):	
 Newly proposed or amended claim(s) would be allowable non-allowable claim(s). 	e if submitted in a separate, timely filed amendment canceling the
7. For purposes of appeal, the proposed amendment(s): a) will how the new or amended claims would be rejected is provided to the status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1.2.4 and 6-9. Claim(s) withdrawn from consideration: 10-17.	Il not be entered, or b) 🛛 will be entered and an explanation of pelow or appended.
AFFIDAVIT OR OTHER EVIDENCE	
 The affidavit or other evidence filed after a final action, but before because applicant failed to provide a showing of good and suffice was not earlier presented. See 37 CFR 1.116(e). 	re or on the date of filing a Notice of Appeal will <u>not</u> be entered cient reasons why the affidavit or other evidence is necessary and
9. The affidavit or other evidence filed after the date of filing a Noti entered because the affidavit or other evidence failed to overcor showing a good and sufficient reasons why it is necessary and vertical process.	me <u>all</u> rejections under appeal and/or appellant fails to provide a
10. The affidavit or other evidence is entered. An explanation of the	e status of the claims after entry is below or attached.
REQUEST FOR RECONSIDERATION/OTHER 11. The request for reconsideration has been considered but does See Continuation Sheet.	NOT place the application in condition for allowance because:
12. Note the attached Information <i>Disclosure Statement</i> (s). (PTO/S13. Other:	SB/08) Paper No(s)
/Zohreh Vakili/	/James D Anderson/
Examiner, Art Unit 1629	Primary Examiner, Art Unit 1629

Continuation of 11. does NOT place the application in condition for allowance because:

Applicants argue that Hayek alone cannot support a prima facie case of obviousness because Hayek alone does not disclose, teach, or suggest a nutritionally balanced pet food composition that comprises astaxanthin. Hayek discloses providing a process for feeding a companion animal such as a dog or a cat a diet containing an effective amount of beta-carotene to enhance immune response and improve the overall health of the animal. See Column 1, lines 45-49. Hayek does mention in its Background that astaxanthin is a carotenoid. See Column 1, lines 16-19. Hayek states carotenoids are absorbed in varying degrees by different species and are known to play a role in modulating the immune system and enhancing the health of the species. See Column 1, lines 16-26. However, Hayek fails to disclose a pet food composition comprising astaxanthin. It states in this Background section that these carotenoids are absorbed by varying species. It does not state dogs or cats. It does not state incorporated astaxanthin into pet food compositions. It then continues its disclosure by stating its invention related to beta-carotene. It fails to disclose any pet food composition comprising astaxanthin.

Applicant's arguments are not persuasive; Applicant is reminded that this is an obviousness rejection not anticipation. The rejection does not indicate that it anticipates, in fact it says it would have been obvious to incorporate one carotenoids for another, wherein the amount of carotenoid used in this case beta-carotene overlaps with the amount of astaxanthin, a carotenoid of the instant claimed invention. Applicant argues Hayek does not mention in its Background that astaxanthin is a carotenoid. Applicant's attention is directed to col. 1, lines 17-19, where it indicates common carotenoids include beta-carotene, lycopene, lutein, zeaxanthin, and astaxanthin. Applicant also argues Hayek states in this Background section that these carotenoids are absorbed by varying species. It does not state dogs or cats. It does not state incorporated astaxanthin into pet food compositions.

Examiner is not persuaded by such argument; Applicant is again reminded this rejection is an obviousness rejection not anticipation. Hayek in its Background section clearly discloses a pet food supplement for enhancing immune response and improving overall health of companion animals such as cats and dogs which includes beneficial amounts of beta-carotene in the animal's diet and as discussed above two of these common carotenoids are astaxanthin and beta-carotene. These beta-carotene one of the common carotenoids are used in the pets food supplement for the same purpose as the astaxanthin used in the composition of the instant claimed invention. Applicant has not provided any factual data that how four known carotenoids would behave differently form each other in a composition to be used as a nutritionally balanced pet food. Applicant has not provided any factual data that one carotenoid can not be predictably replaced by another carotenoid, for example, astaxathin being replaced by beta-carotene and vice versa. The composition of the prior art teaches the use of beta-carotene in a pet food supplement and further teaches there are four other carotenoids that can be used which one of them is astaxanthin. Applicant's amendments and remarks have been carefully considered in their entirety, but fail to be persuasive in establishing error in the propriety of the present rejection..

/Zohreh Vakili/ Examiner, Art Unit 1629